Holen Sie sich die Stockscreener-App
1.17
2.50%
-0.03
Handel nachbörslich:
1.19
0.02
+1.71%
Schlusskurs vom Vortag:
$1.20
Offen:
$1.2
24-Stunden-Volumen:
4.68M
Relative Volume:
0.82
Marktkapitalisierung:
$225.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.78M
KGV:
-1.0935
EPS:
-1.07
Netto-Cashflow:
$-75.59M
1W Leistung:
+21.81%
1M Leistung:
-9.30%
6M Leistung:
-54.47%
1J Leistung:
-75.00%
1-Tages-Spanne:
$1.145
$1.23
1-Wochen-Bereich:
$0.95
$1.25
52-Wochen-Spanne:
$0.91
$4.85
Humacyte Inc Stock (HUMA) Company Profile
Firmenname
Humacyte Inc
Sektor
Branche
Telefon
919-313-9633
Adresse
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Vergleichen Sie HUMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.17 | 231.60M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-27 | Eingeleitet | Barclays | Overweight |
| 2025-05-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2023-12-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-14 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Eingeleitet | Cowen | Outperform |
| 2021-09-24 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-22 | Eingeleitet | BTIG Research | Buy |
| 2021-09-16 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
How buybacks impact Humacyte Inc. Equity Warrant stock value2025 Trade Ideas & Stepwise Trade Execution Plans - ulpravda.ru
Will Humacyte Inc. stock recover faster than peersJuly 2025 Movers & Reliable Intraday Trade Alerts - ulpravda.ru
Can Humacyte Inc. Equity Warrant stock resist market sell offsOptions Play & Fast Gain Swing Trade Alerts - ulpravda.ru
Is Humacyte Inc. Equity Warrant stock undervalued vs historical averagesMarket Performance Recap & Real-Time Buy Signal Notifications - ulpravda.ru
Winners Losers: Can Humacyte Inc. stock deliver sustainable ROE2025 Sector Review & AI Enhanced Trading Alerts - ulpravda.ru
Is Humacyte Inc. Equity Warrant stock a contrarian buyJuly 2025 Closing Moves & Trade Opportunity Analysis - ulpravda.ru
What sentiment indicators say about Humacyte Inc. stockMarket Sentiment Report & Weekly High Return Stock Opportunities - ulpravda.ru
Can Humacyte Inc. stock sustain revenue growthJuly 2025 Volume & Verified Chart Pattern Trade Signals - ulpravda.ru
How strong is Humacyte Inc. Equity Warrant stock revenue growthMarket Performance Report & Precise Buy Zone Identification - ulpravda.ru
Can Humacyte Inc. stock deliver sustainable ROEQuarterly Market Summary & AI Driven Stock Reports - ulpravda.ru
Today's Analyst Ratings: Humacyte (HUMA) Maintains "Buy" Rating - GuruFocus
Preventable surgery complications can drive hospital charges toward $600K - Stock Titan
Patterns Watch: Can Humacyte Inc stock deliver sustainable ROESwing Trade & Risk Managed Investment Signals - moha.gov.vn
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Humacyte rises on Symvess sale to military treatment facility - MSN
Humacyte jumps as DoD issues ECAT listing approval for Symvess - MSN
Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel - MarketScreener
Humacyte Inc announces planned marketing authorization application for Symvess in Israël - MarketScreener
D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte plans to seek approval for vessel product in Israel - Investing.com
Humacyte plans to seek approval for vessel product in Israel By Investing.com - Investing.com India
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - The Manila Times
Humacyte, Inc. (HUMA) Stock Analysis: Exploring A Potential 718% Upside In Biotechnology - DirectorsTalk Interviews
Rate Hike: Is Humacyte Inc stock attractive for income investorsDollar Strength & Daily Entry Point Trade Alerts - moha.gov.vn
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Is Humacyte, Inc. (HUMAW) Stock Down Today? - Meyka
Can Humacyte Inc. Equity Warrant stock maintain growth trajectoryChart Pattern Recognition & Compound Your Gains With Quality Stocks - Bollywood Helpline
Humacyte's (HUMA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Humacyte Reports High Limb Salvage Rates and Durability of Symvess in Long-Term Study Published in JVS-CIT - Quiver Quantitative
Off-the-shelf blood vessel implant helps save injured limbs in study - Stock Titan
Humacyte announces credit facility of $77.5M with Avenue Capital - MSN
Regulatory Ruptures For A Lab-Grown Blood Vessel - The Lever
Lab-Grown Blood Vessel Maker Promotes Risky Off-Label Uses - Jacobin
Humacyte terminates revenue interest agreement - MSN
Humacyte (NASDAQ:HUMA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Is Humacyte Inc. stock attractive for income investorsEarnings Risk Summary & Detailed Earnings Play Strategies - DonanımHaber
Can Humacyte Inc. stock surprise with earnings upsideWeekly Trade Summary & High Accuracy Investment Entry Signals - bolumsonucanavari.com
What catalysts could drive Humacyte Inc. Equity Warrant stock higher2025 Market Outlook & Real-Time Volume Trigger Notifications - DonanımHaber
Humacyte, Inc. (HUMA) Stock Analysis: Biotechnology Visionary with a 607.85% Potential Upside - DirectorsTalk Interviews
Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterQuarterly Growth Report & Daily Profit Maximizing Trade Tips - ulpravda.ru
Published on: 2025-12-19 01:36:49 - Улправда
Is Humacyte Inc. Equity Warrant stock affected by interest rate hikesCEO Change & Reliable Breakout Forecasts - Улправда
Aug Chart Watch: Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterInsider Buying & Capital Efficient Trading Techniques - Улправда
Humacyte enters sales agreement with TD Securities - MSN
Humacyte's US$28m Market Cap Fall Books Insider Losses - simplywall.st
Humacyte’s Big Promise Still Faces A Rocky Road - Finimize
Humacyte Enters Sales Agreement with TD Securities - TipRanks
Humacyte may offer and sell shares of common stock of up to $60 million from time to time through TD Cowen, acting as agent - marketscreener.com
Humacyte (NASDAQ: HUMA) details $60M at the market stock offering - Stock Titan
[424B5] Humacyte, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Investment Review: Is Humacyte Inc Equity Warrant stock a contrarian buyJuly 2025 Short Interest & Expert Curated Trade Setups - moha.gov.vn
Finanzdaten der Humacyte Inc-Aktie (HUMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):